β -arrestin (βarr)-1 and βarr-2, also known as arrestin-2 and arrestin-3, respectively, are the 2 arrestins ubiquitously expressed outside the retina and were initially discovered as terminators of G protein signaling from nonvisual GPCRs (G protein-coupled receptors), after receptor phosphorylation by a GRK (GPCR-kinase), but both are now well documented to mediate signaling from these receptors in their own right. 1, 2 Recent evidence suggests significant functional divergence between the 2 βarr isoforms in various cell types in vitro and in tissues and organs in vivo. 3 Particularly in the heart, βarr1, far more abundantly expressed than βarr2, 4-7 is known to decrease cardiac function, exacerbating post-myocardial infarction (MI) heart failure (HF). 8.9 This occurs via (1) desensitization and downregulation of cardiac βARs (adrenergic receptors), especially of the β 1 AR subtype, the main receptor mediating the stimulatory effects of catecholamines in cardiomyocytes 10 and (2) promotion of cardiac apoptosis and inflammation post-MI. 8 Conversely, βarr2 inhibits apoptosis and inflammation post-MI and seems to (at least) preserve, if not even enhance, cardiac function in post-MI mice. 11 In a previous study, we reported that one of the improved, compared with wild-type mice, cardiac function features of post-MI βarr1-knockout (KO) mice was elevated cardiac SERCA2a (sarco[endo]plasmic reticulum Ca 2+ -ATPase) activity. 8 SERCA2a plays a prominent role in cardiomyocyte functional homeostasis and, specifically, in elevating contractility by increasing the sarcoplasmic reticulum Ca 2+ stores available for the next contraction cycle. 12, 13 This is why its
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dysfunction/downregulation is a molecular hallmark of HF and restoration of its expression and function by gene transfer is actively pursued for HF therapy.
14 SERCA2a undergoes SUMO (small ubiquitin-like modifier)-ylation by SUMO1 at Lys480 and Lys585, modifications essential for preserving its protein stability and enhancing its Ca 2+ pumping activity. 14 In fact, this process is also impaired in chronic HF and strategies that enhance it (eg, via cardiac SUMO1 gene transfer) are also currently explored for HF therapy. 15 Given that βarr2 interacts directly with the SUMO-ligase Ubc9 (and also gets SUMOylated itself), 16, 17 and it seems to enhance SERCA2a activity in vivo, at least in the absence of βarr1, that is, in βarr1-KO hearts, 8 we investigated, in the present study, whether βarr2 can directly affect cardiac SERCA2a SUMOylation and activity.
Methods

Experimental Animals and Surgical Procedures
The animals in this study were handled according to animal welfare regulations and protocols approved by the authors' Institutional Review Boards. An expanded Materials and Methods is available in the online-only Data Supplement.
Statistical Analyses
Data are generally expressed as mean±SEM. Unpaired 2-tailed Student t test and 1-or 2-way ANOVA with Bonferroni test were generally performed for statistical comparisons unless otherwise indicated. For most 3-group statistical comparisons, Dunnett test using SAS version 8.2 software was used, as well. For all tests, a P<0.05 was generally considered to be significant.
Results
βarr2, but Not βarr1, Interacts With Cardiac SERCA2a Enhancing Its SUMOylation In Vivo
Via coimmunoprecipitation experiments in native mouse heart extracts, we found that indeed, βarr2 interacts constitutively with cardiac SERCA2a in vivo while also recruiting Ubc9 to the complex ( Figure 1A ). Importantly, βarr1 is incapable of this because no βarr-SERCA2a interaction is observed in βarr2-KO hearts ( Figure 1A) . Furthermore, the interaction with βarr2 leads to not only enhanced SUMOylation levels but also enhanced protein levels of SERCA2a in vivo because total and SUMOylated SERCA2a levels are significantly higher in βarr1-KO hearts (which lack βarr1 to compete with βarr2 for receptor binding) compared with wild-type hearts and markedly lower in βarr2-KO compared with wild-type hearts ( Figure 1A and 1B) . The finding that only βarr2 interacts with and affects SERCA2a SUMOylation is not surprising, given that βarr2 has several nonreceptor binding partners distinct from βarr1 and, in fact, has many more interacting protein partners than its βarr1 counterpart. 18 This has also been corroborated in recent biophysical studies showing that βarr2, on activation by the same GPCR, engages in additional active conformations than βarr1 does. 19, 20 βarr2-Mediated SERCA2a SUMOylation and Activation Is β 1 AR Activation-Dependent Next, we tested whether this effect of βarr2 on SERCA2a is stimulus dependent, that is, whether it can be modulated by GPCR agonist activation, specifically β 1 AR activation. We chose the β 1 AR, because this is the main AR subtype in the heart that normally activates SERCA2a via the cAMPprotein kinase A pathway, ultimately resulting in PLN (phospholamban) inhibitory phosphorylation. 10, 12 In fact, a recent study showed that among the various cardiac AR subtypes, only the β 1 AR (along with the α 1B AR) is present in all murine ventricular myocytes, whereas the β 2 -and β 3 ARs are mostly absent. 21 Via coimmunoprecipitation experiments in βarr2-overexpressing H9c2 cardiomyocytes, we found that β 1 AR activation with isoproterenol in the presence of the β 2 AR-selective antagonist ICI118,551 acutely increased the interaction of βarr2 with SERCA2a, resulting also in Ubc9 recruitment and SERCA2a SUMOylation ( Figure 1C) . We chose the combination ICI118,551+isoproterenol treatment to ensure that only endogenous β 1 ARs get activated because (1) H9c2 cells also express β 2 ARs, which isoproterenol can also stimulate and (2) there is no completely β 1 AR-selective full agonist available (even dobutamine can also activate the β 2 AR subtype at standard concentrations). 22 Of note, no βarr interaction with SERCA2a was observed in control cells, transfected with AdGFP (adenovirus encoding for green fluorescent protein), because these cells only express βarr1 endogenously 23 ( Figure S1 in the online-only Data Supplement), and βarr1 was again incapable of interacting with SERCA2a, even upon its overexpression ( Figure 1C , see Adβarr1 lanes). In addition, β 1 AR-stimulated SERCA activity was completely abrogated in βarr1-overexpressing H9c2 myocytes ( Figure 1D ), as expected, because this βarr isoform desensitizes the β 1 AR (ie, stops its procontractile cAMP-mediated signaling). In contrast, βarr2 overexpression led, remarkably, to significantly enhanced β 1 AR-dependent SERCA activity compared with control AdGFP-transfected cells ( Figure 1D ). This was because of the enhanced SUMOylation of SERCA2a mediated by βarr2 because βarr2 overexpression could not increase SERCA activity in cells transfected with the double K480/585R SERCA2a SUMOylation-deficient mutant 14 ( Figure 1D ) despite the fact that βarr2 could still interact with this mutant in vitro ( Figure S2 ). Finally, a small molecule activator of SERCA2a SUMOylation, N106, was recently developed and characterized as very promising for HF treatment. 24 βarr2 was found to act additively with this drug at promoting SERCA2a SUMOylation and activity because the effects of N106 on SERCA2a SUMOylation ( Figure 1E ) and activity ( Figure 1F ) were significantly (≈2-fold) augmented in βarr2-expressing myocytes compared with control AdGFPtransfected myocytes.
βarr2-SERCA2a Interaction Is Direct
Next, we sought to dissect further this SERCA2a-βarr2 interaction. GST pull-down experiments ( Figure 2A ) and fluorescence resonance energy transfer experiments in transfected HEK293 cells ( Figure 2B and 2C) confirmed that the interaction is direct. In addition, the lack of interaction with a SERCA2a mutant lacking the N-terminal 313 amino acids (Figure 2A , compare lane 5/full-length βarr2 versus lane 6/truncated βarr2), confirmed also via a yeast 2-hybrid screen (data not shown), indicated that βarr2 binds SERCA2a in this N-terminal region of the pump. This region encompasses one of SERCA2a's 3 cytoplasmic domains, the A (actuator or activation) domain. 25, 26 The A domain is a very short (≈110 amino acids), highly conserved among P-type ATPases, domain that connects via long loops to the transmembrane helix core of SERCA2a and is completely separated from the other 2 main cytoplasmic domains of the pump, the N (nucleotide) domain, which actually contains the SUMOylation sites (K480/K585), and the P (phosphorylation) domain. 25 Therefore, βarr2 most likely does not -ATPase) to stimulate SERCA2a SUMO (small ubiquitin-like modifier)-ylation and activity in vivo and in vitro upon β 1 AR (adrenergic receptor) activation. A and B, Immunoblotting for βarr1/2, Ubc9, SUMO1, and SERCA2a in SERCA2a immunoprecipitates (IPs) prepared from wild-type (WT), βarr1-knockout (KO), or βarr2-KO mouse heart protein extracts. Representative blots are shown in A, and the densitometric quantification of relative SUMOylated SERCA2a (S-SERCA2a) levels is shown in B. Only βarr2, which runs at 50 kDa, could be detected in these SERCA2a IPs. Reverse co-IPs (ie, blotting for SERCA2a in βarr IPs from these heart extracts) confirmed the βarr2-SERCA2a interaction (data not shown). *P<0.05 vs WT; #P<0.05 vs βarr1-KO; n=3 independent experiments per mouse line. C, Immunoblotting for βarr1/2, Ubc9, SUMO1, and SERCA2a in SERCA2a IPs prepared from H9c2 cardiomyocytes, transfected with AdGFP (adenovirus green fluorescent protein), Adβarr1 (adenovirus encoding for β-arrestin1), or Adβarr2, and treated with vehicle, 10 μmol/L ICI118,551 (ICI), or 1 μmol/L isoproterenol (Iso) in the presence of 10 μmol/L ICI for 20 min. D, Maximal β 1 AR-induced (ICI/Iso: 1 μmol/L Iso in the presence of 10 μmol/L ICI for 1 h) SERCA activity in microsomes isolated from H9c2 cardiomyocytes transfected with AdGFP, Adβarr1, Adβarr2, or Adβarr2 plus the SERCA2a K480/585R SUMOylation-deficient mutant. ^P<0.05 vs AdGFP; **P<0.05 vs Adβarr1; n=3 independent measurements per transfection group. No significant difference between the AdGFP and Adβarr2+K480/585R SERCA groups was found. E, SUMOylated SERCA2a (S-SERCA2a) levels in βarr2-expressing (Adβarr2) or control (AdGFP) H9c2 cardiomyocytes treated with 100 nmol/L N106 or vehicle dimethyl sulfoxide (DMSO) for 20 min. F, Maximal SERCA activity in response to 100 nmol/L N106 in these cells. *P<0.05, n=3 independent experiments per transfection group per treatment. IB indicates immunoblotting; IgG lanes, IP with a general IgG antibody (negative control for the SERCA2a co-IP); IP, immunoprecipitation; and βarr2 input, βarr2-overexpressing HEK293 cell lysate (positive control for βarr2 band running exactly at the predicted molecular weight of 50 kDa).
participate in the SUMOylation process of SERCA2a per se but rather binds a small helical portion of the pump, extending into the cytosol, and merely serves as a recruiter of Ubc9 and SUMO1 to the N domain of the protein to carry out the SUMOylation of SERCA2a. Of note, an old proteomic study had identified valosin-containing protein, a transitional endoplasmic reticulum ATPase with similar molecular architecture to SERCA2a, as a nonreceptor binding partner of βarr2 exclusively (not of βarr1). 18 What is more, in that study, βarr2 had been found to interact with valosin-containing protein only upon its activation by receptors. 18 It is thus plausible that the ability to interact with several endoplasmic/sarcoplasmic reticulum-residing ATPases may be a general and unique property of βarr2.
βarr2 Does Not Desensitize the Cardiac β 1 AR
The finding that βarr2 overexpression increased catecholamine-induced SERCA activity ( Figure 1D ), instead of decreasing it, as would be normally expected for a protein that desensitizes βARs, prompted us to investigate whether βarr2 affects the G s protein-dependent, procontractile signaling of β 1 AR or not. Remarkably, we found that β 1 AR-induced cAMP accumulation in βarr2-expressing H9c2 cells was indistinguishable from that of control AdGFP-transfected cells ( Figure 2D ). In contrast, βarr1 overexpression led to an almost complete suppression of cAMP production, as expected, given this βarr isoform desensitizes β 1 ARs ( Figure 2D ). This result strongly suggests that βarr2 does not affect the G s protein/ cAMP-dependent procontractile signaling of the β 1 AR, that is, it does not desensitize β 1 ARs at all in cardiomyocytes.
βarr2 Gene Transfer Ameliorates Cardiac Function and Adverse Remodeling in Post-MI HF by Promoting SERCA2a SUMOylation and Activity In Vivo
Next, we tested whether the ability of βarr2 to stimulate SERCA2a SUMOylation and activity in vitro can translate into increased cardiac function in vivo, especially in the context of chronic HF. To this end, we overexpressed, via adenoviral gene transfer, the wild-type full-length human βarr2 protein specifically in the hearts of adult mice undergoing MI to induce chronic HF, at the time of MI. The murine heart, like almost all other tissues, expresses very little βarr2 protein with βarr1 being essentially the predominant Figure S3 ). 6 Nevertheless, after verifying that βarr2 was significantly overexpressed only in the hearts of post-MI mice receiving the adenovirus encoding for βarr2 ( Figure 3A and Figure S3 ), we examined the functional, structural and molecular statuses of the hearts of these mice at 3 weeks post-MI/gene delivery. As shown in the Table, βarr2 overexpression led to significant improvements of cardiac function and of cardiac dilatation at 3 weeks post-MI compared with control mice receiving AdGFP injection at the time of MI. This increase in cardiac function by βarr2 overexpression Figure 3 . In vivo effects of cardiac βarr2 (β-arrestin)-2 overexpression in post-myocardial infarction (MI) heart failure (HF) mice. A, Representative western blot for the flag-tagged βarr2 transgenic protein in cardiac protein extracts from C57/Bl6 mice at 21-d post-sham operation (Sham) or at 21-d post-MI and AdGFP (adenovirus for green fluorescent protein; MI GFP) or Adβarr2 (adenovirus encoding for β-arrestin2; MI βarr2) gene delivery, confirming robust cardiac-specific βarr2 expression only in the MI βarr2 group. No transgene expression occurred in the liver or lungs of the Adβarr2-injected mice (data not shown). Cont.: HEK293 cell extract overexpressing flag-tagged βarr2, serving as a positive control for the antiflag antibody. Note that, because it was flag-tagged, the βarr2 band ran at a slightly higher than the predicted (50 kDa) molecular weight. Also, because the antibody used was against the flag epitope, endogenous βarrs were not visualized ( Figure S3) . B, Apoptotic cell death in the hearts excised from these mice at 21-d post-MI/gene delivery, as measured by TUNEL (deoxynucleotidyl transferase-mediated dUTP nick end-labeling) performed in the border zone of the infarct. There was no difference in the rate of apoptosis in the remote zone (data not shown). *P<0.05 vs Sham; #P<0.05 vs MIAdGFP; n=5 hearts per group. C and D, Levels of TNF-α (tumor necrosis factor α) (C) and IL-6 (interleukin 6; D) in serum of intracardiac blood from these mice at 21-d post-MI/gene delivery ( Figure S4 ). *P<0.05 vs Sham; #P<0.05 vs MI-AdGFP; n=3 mice per group. E and F, Immunoblotting for PAI-1 (plasminogen activator inhibitor 1) and TGF-β1 (transforming growth factor β1) in cardiac extracts from these mice at 21-d post-MI/gene delivery. Representative blots, including glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as loading control, are shown in E and the densitometric analysis in F. *P<0.05 vs AdGFP; n=3 hearts per group.
was accompanied by marked reductions in cardiac apoptosis ( Figure 3B ), cardiac levels of the proinflammatory cytokines TNF-α (tumor necrosis factor α; Figure 3C ), IL-6 (interleukin 6; Figure 3D ), and IL-1β ( Figure S4 ), activity levels of the cardiac proinflammatory transcription factor NF-κB (nuclear factor-kappa B) 27 ( Figure S5A and S5B) and finally, cardiac adverse remodeling-associated factors (PAI-1 [plasminogen activator inhibitor 1] and TGF-β [transforming growth factor β]; Figure 3E and 3F), at 3 weeks post-MI versus control AdGFP-treated hearts. Together, these results indicate that βarr2 blocked post-MI-associated apoptosis and inflammation and significantly slowed down post-MI adverse remodeling in the hearts it was delivered in. These findings are in line with an earlier study on post-MI βarr2-KO mice, which demonstrated significant cardiac dysfunction, apoptosis, and inflammation in these mice post-MI. 11 Importantly, all of the observed effects can be safely attributed to the exogenously delivered βarr2 because the surgical procedure caused the same extent of myocardial damage between the 2 post-MI groups (as gauged by infarct size measurements at 24 hours post-MI; Figure S6A and S6B). With regard to cardiac SERCA2a function in vivo, βarr2 overexpression significantly increased myocardial SERCA activity ( Figure 4A ) and the levels of SUMOylated and total cardiac SERCA2a ( Figure 4B and 4C) at 3 weeks post-MI, compared with control AdGFP-treated hearts, consistent with the effects of βarr2 on SERCA2a in cardiomyocytes in vitro. The elevation of SERCA activity by βarr2 in vivo was also confirmed in Ca 2+ transient measurements in vitro, in myocytes isolated from hearts of these mice at 3 weeks post-MI. Indeed, the Ca 2+ transient amplitude was significantly increased ( Figure 4D) , and the exponential decay of time constant (τ), a measure of the rate of relaxation, was significantly decreased ( Figure 4E ) in myocytes overexpressing βarr2, compared with myocytes from AdGFPtreated hearts, upon acute β 1 AR activation, both indicating enhanced β 1 AR-dependent SERCA2a activity. Finally, one of the hallmarks of chronic HF is severe βAR dysfunction because of heightened desensitization and downregulation. 8, 10 Consistent with the lack of effect on βAR desensitization and cAMP-dependent signaling observed in H9c2 cardiomyocytes in vitro ( Figure 2D ), cardiac βarr2 overexpression had no effect on either the βAR density ( Figure 5A ) or the total cAMP levels ( Figure 5B ) of the post-MI hearts. This strongly suggests that βarr2 improves cardiac function, apoptosis, inflammation, and adverse remodeling post-MI without hindering the cAMP-dependent procontractile signaling or function of β 1 ARs in the heart.
Discussion
In the present study, we have uncovered a novel, paradigmshifting function of cardiac βarr2: contrary to its far more abundant counterpart βarr1, βarr2 does not affect (desensitize) the G s protein/cAMP-dependent, procontractile signaling of the β 1 AR in cardiac myocytes. Instead, it promotes contractility in its own right by directly interacting with, and inducing SUMOylation of SERCA2a, which results in enhanced SERCA2a protein levels and activity ( Figure 5C ). Thus, βarr2 is not functionally/biologically interchangeable with βarr1 in the heart, as it actually exerts positive inotropy, that is, the exact opposite of what cardiac βarr1 does. Importantly, βarr2, most likely acting in cardiac fibroblasts rather than in cardiac myocytes per se, also inhibits cardiac apoptosis, inflammation, and adverse remodeling post-MI, again contrary to βarr1, which promotes all of these effects in HF 8 ( Figure 5C ). This suggests that cardiac βarr2 may be safely targeted for therapy of both acute and chronic HF, as it seems to act as a positive inotrope with beneficial, reverse remodeling effects in the failing heart. Additionally, given the inextricable interplay between HF (both acute and chronic) and hypertension in humans and the fact that the SERCA isoforms of vascular smooth muscle cells regulate vascular homeostasis and tone, the results of the present study have significant implications for the treatment not only of human HF but also of hypertension and of other cardiovascular conditions.
Of course, further studies are needed to pinpoint which beneficial effects of cardiac βarr2 derive from which cardiac cell type and we plan to investigate this in the future in transgenic mice with cardiac myocyte-specific overexpression of βarr2. However, it is clear from our present study that βarr2 directly promotes contractility in cardiac myocytes, while attenuating inflammation, fibrosis, and other adverse remodeling procedures in fibroblasts and in other cell types of the heart. Of note, we recently reported that the human polymorphic Gly389 β 1 AR, whose procontractile function is markedly lower than the function of its Arg389 β 1 AR counterpart, 28 is incapable of activating βarr2 in transfected neonatal rat cardiomyocytes. 29 Based on our present findings, the ability of the Gly389 β 1 AR variant to only activate the βarr1 isoform may explain (at least in part) why this receptor variant is deficient at stimulating cardiac function in vivo.
Remarkably, βarr2 was also found in the present study not to affect (desensitize) the cardiac β 1 AR cAMP-dependent procontractile signaling. This may seem surprising but is actually consistent with recent studies on βarr2-dependent signaling from βARs indicating that the interaction of this βarr isoform with βARs is very transient and serves to only activate βarr2. 30, 31 Once βarr2 is active, it can dissociate from the β 1 AR and remain active to signal to mitogen-activated protein kinases and other effectors from the cell membrane, that is, pretty much like the G α subunit of a heterotrimeric G protein operates. 30, 31 Under this paradigm, the receptor is free to signal through both G proteins and βarr2 simultaneously, that is, is not, in effect, desensitized (uncoupled from the G proteins). Whether this is a general property of βarr2-mediated signaling (and whether it is shared by βarr1) remains to be determined, but our data indicate that βarr2, and only βarr2, displays this property (at least) in H9c2 cardiomyocytes.
Although very promising in its initial clinical trial stages, SERCA2a gene therapy recently failed to provide significant benefit in patients with HF. 32 However, the SERCA2a gene transfer approach still proved safe for patients (did not increase mortality). Additionally, this trial had dosing and other study design problems complicating interpretation of its results. However, another reason for its failure may have been that the cardiac SERCA2a SUMOylation process, necessary for the proper activation and function of the pump, is also deficient in HF patients.
14 Consequently, gene delivery of SERCA2a alone may be insufficient to restore cardiac function in human HF, and it may have to be combined with βarr2 (or SUMO1) 15 gene delivery to achieve full therapeutic efficacy.
The fact that βarr2 protein is only minimally expressed in the myocardium of most species, including humans, 7 makes cardiac-specific βarr2 gene transfer a very attractive candidate approach for human HF gene therapy. Additional evidence for the potential the βarr2 isoform specifically holds for heart disease therapy was provided by a very recent study on the effect of a βarr2-biased AT 1 R (angiotensin II type 1 receptor) ligand peptide (TRV120067) in an experimental dilated cardiomyopathy murine model. 33 This study reported significant benefits on cardiac function and structure conferred by cardiac βarr2-biased signaling, showing that βarr2 constitutively localizes in cardiac sarcomeres (which are anatomically surrounded by sarcoplasmic reticulum), that this localization is enhanced by receptor ligands that activate βarr2, and that long-term βarr2-biased signaling in the heart results in SERCA2a upregulation. 33 All of these findings are entirely consistent with the main conclusion of this study that βarr2 promotes SERCA2a SUMOylation and activity in the heart, thereby increasing contractility both under normal conditions and in post-MI HF.
Perspectives βarr2, in contrast to its far more abundant in the heart counterpart βarr1, increases cardiac contractility directly, via SERCA2a potentiation, and indirectly, by not impeding the classic cAMP-dependent procontractile signaling of the cardiac β 1 AR. Therefore, cardiac βarr2 pharmacological activation or gene transfer poses as an elegant positive inotropic strategy for acute decompensated HF treatment. At the same time, βarr2 also facilitates reverse remodeling of the infarcted heart, which suggests that its activation may also provide safe augmentation of cardiac function in the context of chronic HF (of the ischemic type, at least). Finally, our present findings indicate that the once promising for chronic HF approaches of SERCA2a restoration gene therapy and of βarr-biased agonist pharmacotherapy each need to be complemented with cardiac-specific βarr2 gene transfer to demonstrate substantial efficacy for chronic post-MI HF improvement.
